ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford purchased 16,471 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were acquired at an average price of $1.84 per share, for a total transaction of $30,306.64. Following the completion of the acquisition, the director now directly owns 26,511 shares in the company, valued at approximately $48,780.24. This represents a 164.05 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Michael Swinford also recently made the following trade(s):
- On Friday, November 22nd, Michael Swinford bought 16,907 shares of ReWalk Robotics stock. The shares were bought at an average cost of $1.83 per share, for a total transaction of $30,939.81.
ReWalk Robotics Stock Performance
Shares of NASDAQ:LFWD opened at $2.06 on Wednesday. The firm has a market cap of $18.14 million, a P/E ratio of -0.83 and a beta of 2.07. ReWalk Robotics Ltd. has a 52-week low of $1.70 and a 52-week high of $9.10. The business’s 50 day simple moving average is $2.56 and its two-hundred day simple moving average is $3.50.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of ReWalk Robotics in a research note on Wednesday, November 13th.
Get Our Latest Report on ReWalk Robotics
Institutional Investors Weigh In On ReWalk Robotics
An institutional investor recently bought a new position in ReWalk Robotics stock. Dimensional Fund Advisors LP acquired a new position in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned approximately 0.16% of ReWalk Robotics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.76% of the company’s stock.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
See Also
- Five stocks we like better than ReWalk Robotics
- What is the Euro STOXX 50 Index?
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- How to Capture the Benefits of Dividend Increases
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.